AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05159440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TORL-2-307-MAB
Description: monoclonal antibody
Study NCT05569408 — intervention group
Intervention type: DRUG
Intervention: EVUSHELD
Description: Tixagevimab (AZD8895) and cilgavimab (AZD1061)
Study NCT05197972 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cardiac coherence program coupled with hypnosis
Description: At home the patient will perform the cardiac coherence sessions between 7 days and a maximum of 15 days before the surgery through the application Respirelax: 3 sessions per day, lasting 5 minutes with a breathing frequency of 6 cycles/min for a period of 7 days minimum and maximum 15 days.~An audio tape read in a hypnotic tone can be listened to by the patient during the cardiac coherence program or at another time of the day (see the text of the audio tape).
Study NCT04599010 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary intervention
Description: energy-restricted diet appropriate for resting metabolic rate using FFM as proxy
Study NCT04971642 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraoral ultrasound
Description: Intraoral ultrasound scanning of the periodontium complex
Study NCT05655299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VTX958 Dose A
Description: Dose A
Study NCT05655299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VTX958 Dose B
Description: Dose B
Study NCT05655299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VTX958 Dose C
Description: Dose C
Study NCT05655299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VTX958 Dose D
Description: Dose D
Study NCT05655299 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04908631 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Transcranial Direct Stimulation
Description: Brain stimulation using low-intensity current via electrodes on scalp to modify neuronal excitability in the underlying cortex. The tDCS system has customizable head gear with disposable, snap-in electrodes wihich can be applied at home without assistance.
Study NCT04908631 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Auditory Training Program
Description: Web-based program uses consonant and vowel recognition and understanding sentences/conversations in quiet and in noise using different talkers, and other types of listening exercises.
Study NCT05754645 — intervention group
Intervention type: OTHER
Intervention: Blood withdrawal
Description: venous punction with blood withdrawal Vaginal and rectal swab, done by patient itself
Study NCT05867368 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HABIT-VR
Description: HABIT-VR is a suite of video games designed on the principals of HABIT treatments. The games are delivered in virtual reality, because these systems provide a way to track the movements of both hands and build software that requires both hands to succeed.
Study NCT05867368 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard HABIT
Description: HABIT is a camp where children play self-select activities that require both hands to succeed.
Study NCT06651541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BZ371A
Description: Formulation with the active ingredient
Study NCT06651541 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Formulation without the active ingredient
Study NCT06462794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CX-801
Description: Investigational drug
Study NCT06462794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Standard of Care Therapy
Study NCT05897658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: Tablets
Study NCT05897658 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets
Study NCT06287580 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chlorthalidone 25 mg
Description: chlorthalidone, 25 mg orally once daily
Study NCT06287580 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet taken orally once daily
Study NCT06138054 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MI-CBTech
Description: Three in-person MI sessions focused on identifying goals for community integration (in the areas of vocational, recreational, social, or independent living activities) and unhelpful thinking that tends to get in the way of those goals, building motivation for goals, introducing participants to the CBT model and its potential benefits, and downloading and orienting them to the mobile phone application.~Six weeks of mobile phone application use to guide participants through CBT. Weekly content will be provided to learn and practice CBT skills to address unhelpful thinking and problem solving to address obstacles to goal attainment. There will be brief content pages worksheets to guide participants through practice. The worksheets will be tailored to each participant, framing the skills around their pre-identified goals and unhelpful thinking patterns. The application will also include access to crisis resources.
Study NCT06138054 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness control
Description: Three in-person supportive therapy sessions focused on empathic listening during client-led discussions of presenting concerns, introducing participants to mindfulness (defined as noticing and paying attention to the present moment without judgment), and downloading and orienting them to the mobile phone application. Participants will be informed of potential benefits of mindfulness, including stress reduction and increased self-awareness.~Six weeks of mindfulness training mobile application use to help participants learn to practice mindfulness through a gradual, self-guided training program. The application offers a library of information about mindfulness, 12 different audio-guided mindfulness exercises, goal-setting and tracking, customizable reminders, and access to crisis resources.
Study NCT05384405 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active iTBS
Description: MagPro X100
Study NCT05384405 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham iTBS
Description: MagPro X100
Study NCT05946057 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Molecular genetic testing and audiometry
Description: Genetic testing and audiometry are the interventions of interest
Study NCT04722939 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cerebral oxygenation
Description: Cerebral oxygenation will be monitored with the FORESIGHT Elite cerebral oximeter during the first 72h of critical illness, and during subsequent hemodialysis sessions
Study NCT05902364 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol 400 and propylene glycol solution/drops
Description: commercially available eye drops
Study NCT04791579 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Description: Fluoroquinolone antibiotic
Study NCT04791579 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill
Study NCT06193096 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental product
Description: Probiotic mix (i3.1) comprising Pediococcus acidilactici KABPTM 021, Lactiplantibacillus plantarum KABPTM 022 and Lactiplantibacillus plantarum KABPTM 023 in a 1:1:1 ratio and with a total concentration of ≥3x10\^9 total colony forming units (CFU) per sachet (stick). Other ingredients are dextrose and maltodextrin as excipients, aroma, flavorings and silicon dioxide. Experimental product will be taken over 4 weeks.
Study NCT06193096 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control product
Description: Placebo product containing dextrose and maltodextrin, aroma, flavorings and silicon dioxide.~Control product will be taken over to weeks
Study NCT06284343 — intervention group
Intervention type: DRUG
Intervention: Anticoagulant
Description: Prescription of pharmacological thromboprophylaxis according to current clinical practice and international guidelines recommendation
Study NCT05773755 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Percept PC DBS system
Description: Open label active Deep Brain Stimulation (DBS)
Study NCT05030129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Hydroxytryptophan
Description: 5-HTP will be over-encapsulated in identical size 00 capsules. During the 5-HTP Treatment Period (Period 3) and 5-HTP/EM Treatment Period (Period 2), subjects will take 1 capsule of 5-HTP 3 times per day.
Study NCT05030129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ergoloid Mesylates
Description: Ergoloid mesylates 1 mg will be mixed with methyl cellulose and placed in a size 00 capsule. During the EM Treatment Period (Period 1) and 5-HTP/EM Treatment Period (Period 2), subjects will take 1 capsule of EM 3 times per day.
Study NCT05030129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo for Ergoloid mesylates
Description: Matching placebo for Ergoloid mesylates will be ascorbic acid powder in identical size 00 capsules. During the 5-HTP Treatment Period (Period 3) and Placebo Treatment Period (Period 4), subjects will take 1 capsule of matching placebo for EM 3 times per day.
Study NCT05030129 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo for Ergoloid mesylates
Description: Matching placebo for Ergoloid mesylates will be ascorbic acid powder in identical size 00 capsules. During the 5-HTP Treatment Period (Period 3) and Placebo Treatment Period (Period 4), subjects will take 1 capsule of matching placebo for EM 3 times per day.
Study NCT05030129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo for 5-Hydroxytryptophan
Description: Matching placebo for 5-Hydroxytryptophan will be ascorbic acid powder in identical size 00 capsules. During the EM Treatment Period (Period 2) and Placebo Treatment Period (Period 4), subjects will take 1 capsule of matching placebo for 5-HTP 3 times per day.
Study NCT05030129 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo for 5-Hydroxytryptophan
Description: Matching placebo for 5-Hydroxytryptophan will be ascorbic acid powder in identical size 00 capsules. During the EM Treatment Period (Period 2) and Placebo Treatment Period (Period 4), subjects will take 1 capsule of matching placebo for 5-HTP 3 times per day.
Study NCT06651606 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive Ratio Training (PRT)
Description: Progressive ratio training (PRT) is used to prevent recurrence of the proxy response when extinction errors occur. PRT involves providing a reinforcer for the proxy response on a geometric progressive ratio (PR) scale. The schedule requirement will increase for the target response each time a reinforcer is delivered. For example, once a reinforcer is delivered on the PR-2 schedule, the requirement will increase to a PR-4, then to a PR-8, -16,~-32, etc.
Study NCT06651606 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Differential Reinforcement of Alternative (DRA) Behavior with Extinction
Description: In DRA with extinction, the proxy for problem behavior is placed on extinction and no longer produces reinforcement. The proxy for communication behavior produces reinforcement on a fixed-ratio 1 schedule of reinforcement.
Study NCT06651853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Large fraction radiotherapy in combined with GM-CSF, Lenalidomide, and Glofitamab
Description: Large fraction radiotherapy is administered at 5Gy/day for 3 days, with one to two courses carried out on a single target lesion as determined by the investigator. Granulocyte-macrophage colony-stimulating factor (GM-CSF) is administered at 400µg per day for 3 days starting on the first day after the end of radiotherapy. Lenalidomide is administered at 25mg per day for 14 days starting on the first day after the end of radiotherapy. Glofitamab is administered starting on the 7th day after the end of radiotherapy.~For cycles 2-6, each cycle is 21 days. GM-CSF is administered at 400µg per day for 3 days starting on the first day of each cycle. Glofitamab is administered at 30mg on the 4th day of each cycle. Lenalidomide is administered at 25mg per day for 14 days starting on the first day after the end of radiotherapy. Treatment consists of 6 cycles or until disease progression, death, intolerable toxicity, withdrawal of informed consent.
Study NCT06652893 — intervention group
Intervention type: DRUG
Intervention: Sinovial
Description: A single intra-articular injection of hybrid HA complex, Sinovial® HL (IBSA Pharmaceuticals, Italy, patent number WO/2012/032151 ) in the knee was performed from the lateral approach to the suprapatellar recess using ultrasound. For the ultrasound-guided infiltration method, a sterile linear probe with a 20 G guide was used to visualize the joint suprapatellar recess and avoid intrasynovial infiltration. The patient was positioned supine with the knee in full extension. From the lateral approach to the suprapatellar recess, HA was then injected into the knee joint, verifying intra-articular positioning in real-time via ultrasound imaging (direct visualization of viscous fluid or air bubbles).~Patients did not receive anti-inflammatory or pain-relieving drugs in the week before the first injection . Patients were evaluated at four time points: at baseline and after 28, 42, 84, and 168 days after the intervention. At each evaluation, clinical data relating to the status of the disea
Study NCT06654167 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low temperature (16℃) group
Description: The exposure group will be exposed to low temperature (16℃) in a chamber for about 2 hours, resting during the whole period.
Study NCT06654167 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate temperature (22℃) group
Description: The exposure group will be exposed to thermoneutral temperature (22℃) in a chamber for about 2 hours, resting during the whole period.
Study NCT06654921 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning
Description: RIC is a non-invasive therapy that performed by an electric auto-control device with cuff placed on arm. RIC procedures consist of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on bilateral arm. The procedure will be performed twice daily for consecutive 6 months after enrollment.
Study NCT06654921 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham remote ischemic conditioning
Description: Sham RIC will be performed by the same electric auto-control device with cuff placed on arm. Sham RIC procedures consist of five cycles of 5-min inflation (60 mmHg) and 5-min deflation of cuff on bilateral arm. The procedure will be performed twice daily for consecutive 6 months after enrollment.
Study NCT06654921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard medication therapy
Description: Standard medication therapy will be performed according to the national and international guidelines.
Study NCT06654921 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Standard medication therapy
Description: Standard medication therapy will be performed according to the national and international guidelines.
Study NCT06654817 — intervention group
Intervention type: DRUG
Intervention: Ofatumumab subcutaneous injection
Description: To compare the efficacy and safety of two treatment strategies: ofatumumab combined with corticosteroids versus corticosteroids along with azathioprine, in pemphigus patients.
Study NCT06654804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perflutren lipid
Description: Bolus injection of contrast during spinal decompression surgery for the treatment of traumatic spinal cord injury. Ultrasound imaging will then be used to collect images of the spinal cord injury to record perfusion, inflow and washout.
Study NCT06654063 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: non-surgical periodontal therapy (SRP)
Description: * The CAL PPD and mSBI will be measured for each patient and will be recorded at baseline and 6 weeks~* all patients will receive supragingival and sub-gingival plaque and calculus debridement (SRP) with an ultrasonic scaler (Various 350; NSK, Japan) and a manual universal curette (Gracey; Hu-Friday, Chicago, USA) where, conventional scaling and root planning (SRP) to the bottom of the pocket of 4 mm or more~* Subgingival saline irrigation will be performed adjunctively to Sub-gingival curettage.
Study NCT06654063 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: non-surgical periodontal therapy (SRP)
Description: * The CAL PPD and mSBI will be measured for each patient and will be recorded at baseline and 6 weeks~* all patients will receive supragingival and sub-gingival plaque and calculus debridement (SRP) with an ultrasonic scaler (Various 350; NSK, Japan) and a manual universal curette (Gracey; Hu-Friday, Chicago, USA) where, conventional scaling and root planning (SRP) to the bottom of the pocket of 4 mm or more~* Subgingival saline irrigation will be performed adjunctively to Sub-gingival curettage.
Study NCT06654063 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: non-surgical periodontal therapy (SRP)+ Omega-3
Description: * The CAL PPD and mSBI will be measured for each patient and will be recorded at baseline and 6 weeks~* all patients will receive supragingival and sub-gingival plaque and calculus debridement (SRP) with an ultrasonic scaler (Various 350; NSK, Japan) and a manual universal curette (Gracey; Hu-Friday, Chicago, USA)~* Subgingival saline irrigation will be performed adjunctively to Sub-gingival curettage.~* Patients will start taking Omega-3 supplements on the day of SRP procedure.
Study NCT06654063 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: non-surgical periodontal therapy (SRP)+ Omega-3
Description: * The CAL PPD and mSBI will be measured for each patient and will be recorded at baseline and 6 weeks~* all patients will receive supragingival and sub-gingival plaque and calculus debridement (SRP) with an ultrasonic scaler (Various 350; NSK, Japan) and a manual universal curette (Gracey; Hu-Friday, Chicago, USA)~* Subgingival saline irrigation will be performed adjunctively to Sub-gingival curettage.~* Patients will start taking Omega-3 supplements on the day of SRP procedure.
Study NCT06654063 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: non-surgical periodontal therapy (SRP)+ Vitamin D
Description: * The CAL PPD and mSBI will be measured for each patient and will be recorded at baseline and 6 weeks~* all patients will receive supragingival and sub-gingival plaque and calculus debridement (SRP) with an ultrasonic scaler (Various 350; NSK, Japan) and a manual universal curette (Gracey; Hu-Friday, Chicago, USA) where, conventional scaling and root planning (SRP) to the bottom of the pocket of 4 mm or more~* Subgingival saline irrigation will be performed adjunctively to Sub-gingival curettage.~* Serum vitamin D levels will be assessed at baseline and 6 weeks after intervention in all groups.
Study NCT06654063 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: non-surgical periodontal therapy (SRP)+ Vitamin D
Description: * The CAL PPD and mSBI will be measured for each patient and will be recorded at baseline and 6 weeks~* all patients will receive supragingival and sub-gingival plaque and calculus debridement (SRP) with an ultrasonic scaler (Various 350; NSK, Japan) and a manual universal curette (Gracey; Hu-Friday, Chicago, USA) where, conventional scaling and root planning (SRP) to the bottom of the pocket of 4 mm or more~* Subgingival saline irrigation will be performed adjunctively to Sub-gingival curettage.~* Serum vitamin D levels will be assessed at baseline and 6 weeks after intervention in all groups.
Study NCT06592196 — intervention group
Intervention type: OTHER
Intervention: stain
Description: This research was conducted in two phases. Initially, a cross-sectional study was performed to assess the correlation between statin usage prior to hospital admission and the initial state of liver enzymes among patients. Subsequently, a retrospective cohort study was undertaken, wherein patients who had not been on statins prior to admission were categorized into two groups based on their statin usage post-admission.
Study NCT06598904 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aroma diffuser with single-note lavender essential oil
Description: In a space of 3\*4\*2.6 cubic meters, positioned 10 cm away from the patient, add 4-6 drops (each drop being 0.05 ml) of 100% concentration single-note lavender essential oil into the aroma diffuser reservoir containing 120 ml of water.
Study NCT06598904 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aroma diffuser with single-note orange essential oil
Description: In a space of 3\*4\*2.6 cubic meters, positioned 10 cm away from the patient, add 4-6 drops (each drop being 0.05 ml) of 100% concentration single-note orange essential oil into the aroma diffuser reservoir containing 120 ml of water.
Study NCT06598904 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Aroma diffuser with deionized water
Description: In a space of 3\*4\*2.6 cubic meters, positioned 10 cm away from the patient, add 4-6 drops (each drop being 0.05 ml) of water into the aroma diffuser reservoir containing 120 ml of deionized water.
Study NCT06589141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MetFORMIN 500 Mg Oral Tablet
Description: Metformin (500 to 2000 mg orally)
Study NCT06589141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GlyBURIDE 2.5 MG Oral Tablet
Description: Glyburide (2.5 mg to 20 mg orally)
Study NCT06593873 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Use of typodont head model in addition to theoretical periodontal education
Description: Use of typodont phantom head model in addition to theoretical periodontal education
Study NCT06593873 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Theoretical periodontal education
Description: Theoretical periodontal training only